Corcept Therapeutics (CORT) Raw Materials (2012 - 2024)

Corcept Therapeutics (CORT) posted Raw Materials of $704000.0 for Q1 2024, down 58.22% sequentially from $1.7 million in Q4 2020.

Corcept Therapeutics (CORT) Raw Materials (2012 - 2024) Analysis & Trends

Corcept Therapeutics has reported Raw Materials for 10 years, with the latest figure at $704000.0 in Q1 2024.

Quarterly Raw Materials changed N/A year-over-year to $704000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $704000.0 (changed N/A YoY) and the FY2020 annual result came in at $1.7 million, up 21.31% from the prior year.
Raw Materials eased to $704000.0 in Q1 2024 per CORT's latest filing, from $1.7 million in the prior quarter.
Over five years, Raw Materials peaked at $1.7 million in Q4 2020 and troughed at $704000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Corcept Therapeutics	12.37 Bn	12.07 Bn	252.09 Mn

Download Data